格隆汇8月18日丨丽珠医药(01513.HK)发布公告，2025年8月18日耗资299万元人民币回购7.31万股A股。 ...

丽珠医药(01513)发布公告，于2025年8月18日斥资299.2万元回购7.31万股A股。 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 麗珠醫藥集團股份有限公司 呈交日期： 2025年8月18日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 01513 | 說明 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | | 佔有關 ...

智通财经APP讯，丽珠医药(01513)发布公告，于2025年8月18日斥资299.2万元回购7.31万股A股。 ...

表格類別： 股票 狀態： 新提交 公司名稱： 麗珠醫藥集團股份有限公司 FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 01513 | 說明 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | | 佔有關事件前的現有已發 行股份（不包括庫存股 份）數目百分比 (註3) | 庫存股份數目 | 每股發行/出售價 (註4) | 已發行股份總數 | | 於下列日期開始時的結存(註1) | 2025年8月15日 | | 299,807,117 | | 0 | | 299,807,117 | | 1). 其他 (請註 ...

Trading Information Summary - On August 15, 2025, the main capital inflow for Lizhu Group was 39.34 million yuan, while retail and speculative capital saw outflows of 28.72 million yuan and 10.62 million yuan respectively [1][3]. Company Announcement Summary - Lizhu Group received the acceptance notice from the National Medical Products Administration for the domestic production registration of JP-1366 tablets, an innovative potassium ion competitive acid blocker (P-CAB) for treating gastroesophageal reflux disease [1][3]. - The clinical study for JP-1366 included 362 patients and demonstrated that its efficacy in esophageal mucosal healing was non-inferior to that of the comparator drug, Naisan, while significantly improving symptoms such as heartburn and reflux [1][3]. - Cumulative R&D expenses for JP-1366 reached approximately 185.21 million yuan as of the announcement date [1]. - According to IQVIA data, the domestic terminal sales for P-CAB are projected to be approximately 1.25 billion yuan in 2024, reflecting a year-on-year growth of 81.22%, with Q1 2025 sales estimated at around 394.35 million yuan, also showing an 81.63% increase year-on-year [1].

Core Viewpoint - Lijun Group's JP-1366 tablet has received acceptance for its domestic production drug registration application, indicating progress in its development pipeline for treating gastroesophageal reflux disease [1][2] Company Announcements - Lijun Group's JP-1366 tablet registration application was accepted by the National Medical Products Administration, with a cumulative R&D investment of approximately RMB 185.21 million [1] - The company has initiated a Phase III clinical study for JP-1366, involving 362 patients, showing non-inferiority in esophageal mucosal healing rates compared to the control drug, Naisan [2] Market Performance - As of August 15, 2025, Lijun Group's stock closed at RMB 40.1, a 0.25% increase from the previous week, with a total market capitalization of RMB 36.254 billion [1] - The stock reached a weekly high of RMB 40.75 and a low of RMB 39.26, ranking 15th in the chemical pharmaceutical sector and 453rd among A-shares [1] Sales Projections - According to IQVIA data, the domestic terminal sales for P-CABs are projected to reach approximately RMB 1.248 billion in 2024, reflecting a year-on-year growth of 81.22%, with Q1 2025 sales estimated at RMB 394.35 million, up 81.63% year-on-year [2]

Group 1 - The core point of the announcement is that the company’s subsidiary, Lijun Pharmaceutical Group Co., Ltd., has received a notice of acceptance from the National Medical Products Administration for the domestic production registration of JP-1366 tablets, which are indicated for gastroesophageal reflux disease [1][2] Group 2 - JP-1366 tablets are an innovative potassium-competitive acid blocker (P-CAB) that effectively inhibits gastric acid secretion, promoting esophageal mucosal healing and improving reflux symptoms [2][3] - A Phase III clinical study has been initiated to compare JP-1366 tablets with Esomeprazole magnesium enteric-coated tablets in Chinese patients with gastroesophageal reflux disease, involving 362 patients [2] - The clinical study results indicate that JP-1366 tablets achieve a mucosal healing rate comparable to Esomeprazole within 8 weeks and significantly improve symptoms such as heartburn and reflux [2][3] Group 3 - The market for P-CABs in China is projected to reach approximately RMB 1.25 billion in 2024, reflecting a year-on-year growth of 81.22% from 2023 [4] - The first quarter of 2025 is expected to see P-CAB sales of around RMB 394.35 million, marking an 81.63% increase compared to the first quarter of 2024 [4] - The introduction of JP-1366 tablets will enhance the company’s product pipeline in the gastrointestinal field, providing more comprehensive treatment options [4]

Core Viewpoint - Lijun Pharmaceutical Group Co., Ltd. has received a notice of acceptance from the National Medical Products Administration for the domestic production registration of JP-1366 tablets, an innovative potassium ion competitive acid blocker for the treatment of gastroesophageal reflux disease [1][2]. Group 1: Drug Registration and Approval - The drug name is JP-1366 tablets, with a specification of 20mg, aimed at treating reflux esophagitis [1]. - The application for domestic production registration has been accepted by the National Medical Products Administration, indicating a positive step towards market entry [1]. Group 2: Drug Development and Clinical Trials - JP-1366 tablets are designed to inhibit gastric acid secretion by blocking the K(+) channel of the H(+), K(+)-ATPase, effectively promoting esophageal mucosal healing and alleviating reflux symptoms [2]. - A Phase III clinical trial involving 362 patients with reflux esophagitis has been initiated, with results showing that JP-1366 tablets achieve a mucosal healing rate comparable to the existing treatment, Esomeprazole [2][3]. Group 3: Financial Investment in R&D - The total research and development investment for JP-1366 tablets has reached approximately RMB 185.21 million [4]. Group 4: Market Situation - Proton pump inhibitors (PPIs) and potassium ion competitive acid blockers (P-CABs) are recognized as first-line treatment options for gastroesophageal reflux disease in clinical guidelines [5]. - The estimated domestic terminal sales for P-CABs in 2024 are approximately RMB 1.25 billion, reflecting a year-on-year growth of 81.22% [5][6]. - In the first quarter of 2025, the estimated domestic terminal sales for P-CABs are around RMB 394.35 million, showing an increase of 81.63% compared to the same period in 2024 [6].

Group 1 - The latest stock price of Lizhu Group is 40.10 yuan, an increase of 1.13% compared to the previous trading day, with a trading volume of 4.24 billion yuan [1] - Lizhu Group is primarily engaged in the research, production, and sales of pharmaceutical products, covering areas such as chemical preparations, active pharmaceutical ingredients, diagnostic reagents, and equipment [1] - On August 15, Lizhu Group announced that its research and development application for the drug JP-1366 has been accepted by the National Medical Products Administration, targeting gastroesophageal reflux disease [1] Group 2 - The cumulative R&D investment for the drug JP-1366 has reached 185 million yuan [1] - On the same day, the net inflow of main funds into Lizhu Group was 39.34 million yuan, with a net inflow of 20.07 million yuan over the past five days [1]